ArticleFrontiers in immunology2020
Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05896878 (The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients), which is not on this map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection.Inflammopharmacology · 2022Pooled it
- Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial.Stem cell research & therapy · 2022Trial
- Cholinergic Signaling Attenuates Pro-Inflammatory Interleukin-8 Response in Colonic Epithelial Cells.Frontiers in immunology · 2021Trial
- Smartphone-Assisted Digital Image-Based Optical Biosensor Array for Quantification of Interleukin-8 Using Antibody-Conjugated Gold Nanoparticles.Micromachines · 2026Article
- Respiratory Biomarkers: An Opportunity for Patient-Centric Microsampling Approach for Treatment Optimization.Clinical and translational science · 2026Review
- A quantitative metabolic signature of host response during SARS-CoV-2 infection and recovery.iScience · 2026Article
- Development and validation of a cytokine-driven predictive model for COVID-19 severity.BMC infectious diseases · 2026Article
- Disentangling depression in women with diabetes: evidence for measure-dependent associations with interleukin-4 and common inflammatory biomarkers.Frontiers in psychiatry · 2026Article
- Association of IL-1β, IL-6, IL-8, IL-12, TNF-α, and IFN-α With Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome.Biomarker insights · 2026Article
- Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates.PloS one · 2026Article
- Article
- SARS-CoV-2 innate immune recognition and implications for respiratory health.Cytokine & growth factor reviews · 2025Review
- Megakaryocyte phenotyping in response to SARS-CoV-2 variants.Platelets · 2025Article
- Relationship between body mass index, gray matter volume and peripheral inflammation in patients with post-COVID condition.Brain, behavior, & immunity - health · 2025Article
- Multiplex Targeted Proteomic Analysis of Cytokine Ratios for ICU Mortality in Severe COVID-19.Proteomes · 2025Article
- SARS-CoV-2 spike treatment and transfection impairs airway epithelial repair.ERJ open research · 2025Article
- Integrated analysis of COVID-19 multi-omics data for eQTLs reveals genetic mechanisms underlying disease severity.bioRxiv : the preprint server for biology · 2025Article
- Review
- Preliminary results and a theoretical perspective of co‑treatment using a miR‑93‑5p mimic and aged garlic extract to inhibit the expression of the pro‑inflammatory interleukin‑8 gene.Experimental and therapeutic medicine · 2025Article
- Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The widespread prevalence of coronavirus disease-2019 (COVID-19) which is caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has resulted in a severe global public health emergency. However, there are no sensitive biomarkers to predict the disease prognosis of COVID-19 patients. Here, we have identified interleukin-8 (IL-8) as a biomarker candidate to predict different disease severity and prognosis of COVID-19 patients. While serum IL-6 become obviously elevated in severe COVID-19 patients, serum IL-8 was easily detectible in COVID-19 patients with mild syndromes. Furthermore, lL-8 levels correlated better than IL-6 levels with the overall clinical disease scores at different stages of the same COVID-19 patients. Thus, our studies suggest that IL-6 and IL-8 can be respectively used as biomarkers for severe COVID-19 patients and for COVID-19 disease prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.